The 2026 Texas Lung Cancer Conference website is up with faculty & agenda. Join my co-chair, Dr. Tina Cascone, and me with 100+ expert faculty on April 9-11, 2026 at Austin City Limits for all the lung cancer updates you need! #TexasLung26 @TLCconference https://t.co/SkHAEIpiYv

Starting now ⭐️ Fueling the Future: A Networking Breakfast for Trainees and Early Professionals ⭐️ at #NACLC25 with Drs. @HwakeleeMD @christinemphmd @ASridharMD @kamarroneMD Jennifer Li and Seungjun Kim

Surgery vs SBRT #NACLC25 “In the surgical literature the rates of nodal upstaging are never zero.” @BTongMD This point alone to me (identifying pts with more advanced disease who may benefit from systemic therapy) will always make surgery preferable to SBRT in operable pts.

Dear friend & colleague @maraantonoff shares her expertise on the evolving role of surgery in stage 4 disease. #NACLC25 @IASLC

🎉Excited to share safety & efficacy of my Ph 1/2 clinical trial of amivantamab + ALK, ROS, or RET TKIs! ❗️No new safety signals (VTE, ILD, liver tox) seen with combo. IRR universal, but ami dose reduction low (11%) ⭐️ORR=22%, DCR=100% 🔬More translational data coming!!

Honored to serve as the discussant for two outstanding junior investigators at #NACLC25. Their dedication, curiosity, and innovation inspire the future of thoracic oncology. @IASLC @YoungLungCancer

#NACLC25 For treatment naive cohort, no G3-4 TRAEs and only 5% in previously treated cohort. TRAEs in ≥ 10% of pts were only infusion reactions (only 1 grade 3+) and diarrhea in ~20% (mostly G1-2). Only 1 patient in each cohort discontinued due to TRAE.

In eNRGy, zenocutuzumab responses were numerically longer in the 1L setting. Median duration of response was 17.1m for treatment naive NRG1+ NSCLC and 7.4m in previously treated setting. Median time to response 1.8-1.9 months. #NACLC25

In treatment naive cohort, RR 35% with CBR 65% (here, clinical benefit defined as stable disease lasting at least 6 months). In my experience, NRG1+ NSCLC is difficult to measure due to frequent lymphangitic spread - I think CBR is a good reflection of benefit. #NACLC25

Zenocutuzumab is a HER2/HER3 bispecific antibody that prevents NRG1 from binding to HER3 and triggering heterodimerization with HER2 and downstream signaling. eNRGy was a single arm phase II of zenocutuzumab 750mg IV q2w and included 20 pts with treatment naive NSCLC. #NACLC25

Grateful to present an update on the phase II eNRGy trial at #NACLC25: zenocutuzumab in pts with treatment-naive, NRG1-fusion positive NSCLC. Zenocutuzumab was FDA approved December 2024 in previously treated NSCLC and pancreatic cancer but did include some treatment naive.

Poster session of #NACLC25 - proud to present latest data on zidesamtinib (NVL-520) in ROS1 NSCLC. In pts with prior ROS1 TKI, RR 44% (including responses post repotrectinib and taletrectinib). As first-line therapy, zidesamtinib RR 89%, 1y DOR rate 96%, intracranial RR 83%.

Poster session of #NACLC25 - update on pralsetinib in RET fusion NSCLC (ARROW trial) in pts with prior immunotherapy. RR 64%, DCR 91%, mOS 30.9m with no AEs of hypersensitivity reported. Grateful to be included in this subanalysis.

Poster session of #NACLC25 - glad to present a Trials in Progress poster of the ROSETTA Lung-02 trial: first-line pumitamig (BNT327/BMS986545 - a PD-L1 x VEGF bispecific antibody) + chemotherapy in advaned NSCLC. Design for this phase II/III trial shown here.

@StephenVLiu presents efficacy of zenocutuzumab for untreated NRG1 fusions at #NACLC25. This is an active drug, binding HER2-HER3 is a rationale strategy. #RNA based testing critical to detect these ultra-rare fusions. @IASLC | @ASCO @lcsmchat @OncoAlert @OncogeneCancer @OncLive

Join us live on X from #NACLC25 tonight at 8:30 PM CST for our lung cancer #IDEOXchange discussing the latest developments with Drs. @ChristineBestv1 @theabzlab @lungoncdoc @GavittWoodard @marinagarassino @ajuloorimd @NarjustFlorezMD @hjrossmd @dramycummings @hari_keshava

Wishing #NACLC25 Conference Chair @ErinGillaspie a wonderful birthday! 🎂 Oral abstract presentations are happening now!

Sharing the podium at the oral abstract session of #NACLC25 with friend Dr. Byoung Chul Cho.

Great debates at #NACLC25 are underway! Thrilled to see my dear friend & Miami Cancer Institute’s NEWEST thoracic oncology lead, Dr. @BrunaPellini, deliver an elegant presentation on risk-adapted management for early-stage resectable NSCLC.

Las voces que están transformando la oncología torácica en América Latina. Conversamos sobre liderazgo, retos, sororidad y el poder de abrir camino para las que vienen. 💛🎙️ #MujeresEnOncología @IASLC @Florez_Lab @moniccastrog @loladelamata @maritza_rramos

Watch Dr. Stephen V. Liu (@StephenVLiu), Dr. Jennifer W. Carlisle (@JennyCarlisleMD), & Dr. Anne Chiang (@Annechiangmd) discuss the latest #SCLC updates from #NACLC25 #MedEd – to participate, visit: https://t.co/ci85sCVHi7